LARVOL is pleased to present a moderated discussion with top oncologists following ASCO's Annual Meeting 2021. In the video below, Dr. Kinisha Gala, Dr. Matthew Galsky, and Dr. Ashish Kamat discuss the practice-changing impact of ASCO presentations in GU cancer.
On June 7, 2021, LARVOL hosted an Oncology Panel to discuss the top genitourinary (GU) cancer clinical trial abstracts presented during the American Society of Clinical Oncology (ASCO) Annual Meeting 2021, held on June 4-8, 2021. Dr. Kinisha Gala from LARVOL moderated the discussion between GU cancer KOLs Dr. Matthew Galsky from Mount Sinai and Dr. Ashish Kamat from MD Anderson Cancer Center.
The discussion covered ASCO abstract #4508 First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study, ASCO abstract #4517 Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): A multicenter, single-arm, phase 2 trial and ASCO abstract #4503 Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257.
Watch this video for the full discussion:
Our ASCO Panel Series covered six therapeutic areas including GU cancer. Click below to read more about them and watch their video analysis.
The advent of precision oncology is marked by many new changes and improvements in diagnostic, prognostic and treatment methods for cancer patients. Researchers looking to bring new drugs to market are now also privy to a vast database of material from previously conducted studies thanks to a push forward in research collaborations and the creation of shared data hubs.